SLC5A2 and polycythemia: Among the 6787 patients included in this retrospective study at Bundang Seoul National University Hospital, 1145 (16.9%) developed erythrocytosis after initiating SGLT-2 inhibitor therapy, while 5642 (83.1%) did not.